Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...
Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...
This medication is an anticoagulant ... avoid coadministration with strong dual inhibitors. • Discontinuing eliquis in patients without adequate continuous anticoagulation increases risk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback